Elebsiran

Elebsiran (VIR-2218) is an investigational subcutaneously administered HBV-targeting small interfering RNA developed by Vir Biotechnology and Alnylam collaboration programs. It is being evaluated in hepatitis delta and hepatitis B clinical studies, including combination regimens with tobevibart. The candidate remains unapproved for marketing.

Drug Class

HBV-targeting small interfering RNA (siRNA)

Approval Status

Investigational; FDA IND cleared and Fast Track designated for combination use in chronic hepatitis delta, but not approved

Mechanism of Action

Designed to degrade HBV RNA transcripts and limit hepatitis B surface antigen production, with potential direct antiviral activity against HBV and HDV